Liliana Montella

Dr. Liliana Montella

Naples 2 Local Health Unit, Oncology Operative Unit, “Santa Maria delle Grazie” Hospital
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RARaffale Addeo
Raffale Addeo
Michele CaragliaMichele Caraglia
Michele Caraglia
SBSergio Bellini
Sergio Bellini
AAAlberto Abbruzzese
Alberto Abbruzzese
BVBruno Vincenzi
Bruno Vincenzi
SPSalvatore Del Prete
Salvatore Del Prete
Purpose: Approximately 30% to 40% patients with a superficial bladder cancer treated with Bacille Calmette-Guerin (BCG) or epirubicin do not respond; of the initial responders, 35% have a relapse within 5 years. We compare the therapeutic efficacy and toxicity of intravescical infusions of gemcitabine (GEM) with mitomycin (MMC) in patients with a recurrent superficial bladder cancer.Patients and Methods: Patients with a history of a previously treated, recurrent Ta-T1, G1-G3 bladder transitional cell carcinoma were enrolled in the study. The patients received a 6-week course of GEM infusions or 4-week course of MMC. In both arms, for the initial responders who remained free of recurrences, maintenance therapy consisted of 10 monthly treatments during the first year.Results: A total of 120 patients were enrolled and randomly assigned to either the MMC or GEM treatment arm. At the end of the study, 109 patients (55 in MMC and 54 in GEM) were assessable. The median duration of follow-up was 36 months for either arm. In the GEM arm, 39 (72%) of 54 patients remained free of recurrence versus 33 (61%) of 55 in MMC arm. Among patients with recurrences, 10 in the MMC arm and six in the GEM arm also had a progressive disease by stage. The incidence of chemical cystitis in the MMC arm was statistically higher than in the GEM arm (P = .012).Conclusion: This study demonstrates that GEM has better efficacy and lower toxicity than MMC; therefore, GEM appears as a logical candidate for intrabladder therapy in patients with refractory transitional cancer.

1 January 2010 in The Oncologist
Verified
Journal Article
Closed access
PDF file
BVBruno Vincenzi
Bruno Vincenzi
SDSantini Daniele
Santini Daniele
ARAntonio Russo
Antonio Russo
RARaffaele Addeo
Raffaele Addeo
FGFrancesco Giuliani
Francesco Giuliani
GTGiuseppe Tonini
Giuseppe Tonini
Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response plus stable disease) and TTP. Results. Sixty-five HCC patients treated with sorafenib were included in this analysis: 47 (73.3%) received sorafenib after failure of some local treatment, whereas 18 (27.7%) received it as first-line treatment. Twenty-nine patients developed at least grade 1 skin toxicity (rash, 13; HFSR, 16). In patients who developed skin toxicity, the tumor control rate was 48.3%, versus 19.4% in patients without cutaneous side effects. The median TTP was 8.1 months in the group of patients with skin toxicity versus 4.0 months in those without skin toxicity. This difference was also statistically significant on multivariate analysis. A borderline statistically significant difference was also observed in terms of OS in patients with early skin toxicity. Conclusions. Skin toxicity should be closely monitored in HCC patients treated with sorafenib in relation to its potential role as a surrogate marker of efficacy.

11 March 2002 in Cancer
Verified
Journal Article
Open access
PDF file
GPGiovannella Palmieri
Giovannella Palmieri
LMLiliana Montella
Liliana Montella
AMAngelo Martignetti
Angelo Martignetti
PMPietro Muto
Pietro Muto
DVDolores Di Vizio
Dolores Di Vizio
SLSecondo Lastoria
Secondo Lastoria
BACKGROUND: Therapeutic options to cure advanced, recurrent, and metastatic thymic tumors are limited. Evidence of a high uptake of indium‐labeled octreotide (111In‐DTPA‐D‐Phe1‐octreotide) in thymic tumors and the curative application of somatostatin analogs and prednisone in one patient with thymoma and pure red cell aplasia led the authors to start a Phase II study.METHODS: Sixteen patients with advanced thymic tumors, unresponsive to conventional chemotherapeutic regimens, were enrolled in the study. The schedule includes administration of somatostatin analog octreotide (1.5 mg/day subcutaneously) associated with prednisone (0.6 mg/kg/day orally for 3 months, 0.2 mg/kg/day orally during follow‐up). In 8 cases, octreotide was replaced by the long‐acting analog lanreotide (30 mg/every 14 days intramuscolarly). Treatment was prolonged until progression of disease was documented. Overall response rate, survival, progression free survival, and toxicity were evaluated.RESULTS: The overall response rate among 16 evaluable patients was 37%. One patient (6%) had a complete response, 5 (31%) had a partial response, 6 obtained a stabilization of disease, and 4 progressed during the treatment. After a median follow‐up of 43 months, the median survival was 15 months, and median time to progression was 14 months. Treatment was generally well tolerated with acceptable toxicity: cholelithiasis (1 patient), Grade 2 cushingoid appearance (3 patients), Grade 1 diarrhea (5 patients), Grade 2 hyperglycemia (3 patients).CONCLUSIONS: Treatment with somatostatin analogs and prednisone has shown efficacy in patients with recurrent and metastatic malignant thymic tumors refractory to standard therapeutic options. The results obtained are very satisfactory given the lack of effective alternative treatments. Such therapy is not burdened by the same toxicity of chemotherapy; thus, it can be administered to heavily pretreated patients. Somatostatin analogs and prednisone are well tolerated, and the long‐acting analog lanreotide, which requires fewer injections, improves patients' compliance. Cancer 2002;94:1414–20. © 2002 American Cancer Society.DOI 10.1002/cncr.10374

1 August 2010 in Clinical Breast Cancer
Verified
Journal Article
Closed access
RARaffale Addeo
Raffale Addeo
ASAlessandro Sgambato
Alessandro Sgambato
GCGregorio Cennamo
Gregorio Cennamo
LMLiliana Montella
Liliana Montella
VFVincenzo Faiola
Vincenzo Faiola
SPSalvatore Del Prete
Salvatore Del Prete

30 December 2009 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSalvatore Del Prete
Salvatore Del Prete
LMLiliana Montella
Liliana Montella
Michele CaragliaMichele Caraglia
Michele Caraglia
LMLuigi Maiorino
Luigi Maiorino
GCGregorio Cennamo
Gregorio Cennamo
RARaffaele Addeo
Raffaele Addeo

28 April 2011 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Michele CaragliaMichele Caraglia
Michele Caraglia
GGG Giuberti
G Giuberti
MMM Marra
M Marra
RARaffale Addeo
Raffale Addeo
LMLiliana Montella
Liliana Montella
PSPaola Stiuso
Paola Stiuso
We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients. In this work, we have studied if oxidative stress in both serum and peripheral blood mononuclear cells (PBMC) and pERK activation status in PBMC could be predictive of response. In the 20 responsive patients, the decrease of reactive oxygen species levels was already detectable after 10 days (T10) from the beginning of sorafenib administration, and this effect was enhanced by the combined treatment with sorafenib+octreotide LAR (T21). This effect correlated with the modulation of superoxide dismutase (SOD) activity (physiological scavenger of O2−) and of serum nitric oxide (NO) levels. Sorafenib alone induced an increase of about 40% of NO levels and of about two-fold of SOD activity in responsive patients, and both effects were significantly potentiated by the combined treatment. We found a gradual reduction of Erk1/2 activity, as evaluated by cytofluorimetric analysis, in 15 responsive patients reaching about 50% maximal decrease at T21. On the other hand, in 17 resistant patients, Erk1/2 activity was about 80% increased at T21. The determination of both the oxidative stress status and pERK activity in PBMC has high value in the prediction of response to sorafenib+octreotide therapy in HCC patients.